Pharmaceuticals, Biotechnology & Life Sciences

BioNTech’s trastuzumab pamirtecan shows 48% response in HER2‑positive recurrent endometrial cancer, while a new Boehringer partnership targets small‑cell lung cancer, and a €1.9 bn court win boosts its oncology pivot.

Johnson & Johnson Q1 earnings preview: investors eye modest revenue lift, EPS growth, and robust cash‑flow amid oncology gains and strong analyst sentiment.

Alterity Therapeutics: Explore its volatile stock, negative P/E and the battle to deliver Alzheimer’s therapies amid financial challenges.

CorMedix, a Nasdaq‑listed biopharma, showcases its cutting‑edge anti‑infective pipeline—DefenCath®, REZZAYO®—and strategic Melinta acquisition at the 2026 Needham Virtual Healthcare Conference, spotlighting growth in infectious & inflammatory therap…

Explore KALA BIO’s dramatic stock plunge, negative P/E and the hurdles facing its mucosal drug‑delivery tech—what it means for investors and the future of biotech.

Creative Medical Technology Holdings: regenerative medicine promise meets steep financial hurdles. 2026 stock slump, negative P/E, and investor caution reveal the risks and potential of a biotech innovator.

Vanda Pharmaceuticals launches Thetis trial for tradipitant, a small‑molecule anti‑emetic, and challenges FDA’s proposed review‑time extension, aiming to speed GLP‑1 therapy access.

Merck KGaA’s resilient healthcare pipeline, expanding lipid‑nanoparticle platform and dividend‑friendly policy drive medium‑term value amid market volatility.

Predilife SA raises €900k via 8.5% convertible bonds, secures FDA approval for DenSeeRisk, and validates its MammoRisk breast‑cancer platform—boosting biotech growth.

Read how Candel Therapeutics’ new ingredient partnership could boost its phase‑III antitumor drug and what it means for investors and the oncology market.